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OBJECTIVES A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was performed to
evaluate the effects of the angiotensin II receptor blocker, valsartan, in the patients with
chronic heart failure (HF) not receiving angiotensin-converting enzyme (ACE) inhibitors.
BACKGROUND The ACE inhibitors reduce mortality and morbidity in patients with HF. Nonetheless, nearly
20% of potentially eligible patients may not be prescribed ACE inhibitors.
RESULTS Val-HeFT was an international, randomized, double-blinded trial that compared valsartan
with placebo when added to the prescribed treatment of patients with HF. The two primary
end points of the study were all-cause mortality and the composite of all-cause mortality and
morbidity (sudden death with resuscitation, hospital admission for HF, or administration of
intravenous inotropic or vasodilator drugs for4 h without hospital admission). Of the 5,010
patients enrolled in the trial, 366 (7.3%) were not treated with ACE inhibitors at baseline.
The effects of valsartan on the primary and secondary end points of the study were assessed
in this subgroup of patients.
RESULTS Both all-cause mortality and combined mortality and morbidity for patients not treated with
ACE inhibitors were significantly reduced in the valsartan treatment group compared with
the placebo group (17.3% vs. 27.1%, p 0.017 and 24.9% vs. 42.5%, p 0.001, respectively).
Consistent with the data on clinical events, patients randomized to valsartan showed
improvements in physiologic variables, such as ejection fraction, left ventricular internal
diameter in diastole, and plasma neurohormone levels. Permanent discontinuation of study
treatment because of adverse experiences was comparable between the two groups.
CONCLUSIONS Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable
effect of an angiotensin receptor blocker on mortality and morbidity in patients with HF not
treated with ACE inhibitors. Based on these results, valsartan appears to be an effective
therapy in ACE inhibitor-intolerant patients. (J Am Coll Cardiol 2002;40:1414–21)
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Angiotensin-converting enzyme (ACE) inhibitors reduce
the mortality and morbidity of patients with chronic heart
failure (HF) (1). The mechanisms of the beneficial effect of
ACE inhibitors are not fully established, but it is likely that
inhibition of angiotensin II production is at least partially
responsible (2,3). However, nearly 20% of potentially eligi-
ble patients are not prescribed ACE inhibitors, presumably
because of actual or perceived intolerance to the drug (4,5).
See page 1422
Angiotensin receptor blockers (ARBs) produce a more
complete blockade of the effects of angiotensin II by a
combination of both ACE-dependent and non–ACE-
dependent pathways, but they lack some of the effects
thought to be important to the benefits of ACE inhibitors,
such as inhibition of bradykinin degradation (6). Moreover,
patients intolerant to ACE inhibitors appear to tolerate
ARBs relatively well (7). However, it is not clear whether
the treatment of ACE inhibitor-intolerant patients with
ARBs leads to a reduction in morbidity and mortality.
The Valsartan Heart Failure Trial (Val-HeFT) showed
that the ARB, valsartan, significantly reduced the combined
end point of mortality and morbidity by 13.2% when added
to the prescribed therapy of patients with HF (8,9). In this
trial, 7% of the patients were not receiving an ACE
inhibitor as part of their background therapy (9). Although
the reasons for withholding an ACE inhibitor in this group
were not established, given the kind of centers involved and
the high rate of ACE inhibitor usage in the overall popu-
lation, it is likely that ACE inhibitor intolerance was the
most common reason.
This report evaluates the effects of valsartan in patients
not receiving ACE inhibitors on the primary end point of
all-cause mortality and the composite end point of all-cause
mortality and morbidity, defined as sudden death with
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resuscitation, hospital admission for HF, or administration
of intravenous inotropic or vasodilator drugs for 4 h
without hospital admission. The effects of valsartan were
also evaluated in terms of neurohormone levels, left ventric-
ular internal diastolic diameter (LVIDD) adjusted for body
surface area (BSA), left ventricular ejection fraction
(LVEF), and quality of life.
METHODS
Design and eligibility. Val-HeFT was a randomized,
placebo-controlled, double-blinded, parallel-arm trial. A
detailed description of the study protocol has been reported
elsewhere (8). A total of 5,010 patients were randomized to
either valsartan or placebo. The investigation conformed to
the principles of the Declaration of Helsinki.
Men and women18 years old with a history and clinical
findings of HF for at least three months before screening
were eligible. Patients were in New York Heart Association
(NYHA) functional classes II to IV, were clinically stable,
and were receiving a fixed-dose drug regimen that might
include ACE inhibitors, diuretics, digoxin, and beta-
blockers for at least two weeks. To be included in the trial,
patients had to have documented LVEF 40% and echo-
cardiographically measured LVIDD/BSA 2.9 cm/m2.
Echocardiograms were analyzed locally after each center
underwent validation of technical and reader quality by
centralized core laboratories that also monitored quality
during the study.
The present analysis is focused on the 366 patients (7.3%
of the total trial population) who were not treated with
ACE inhibitors.
Placebo run-in period and dose titration. Patients were
assessed for two to four weeks to confirm their eligibility,
stability, and compliance while taking single-blinded pla-
cebo twice daily. Valsartan was initiated at 40 mg twice daily
and was doubled every two weeks to a target dose of 160 mg
twice daily. Criteria for upward titration included standing
systolic blood pressure of 90 mm Hg, no symptoms of
hypotension, and serum creatinine2.0 mg/dl or no greater
than 50% above baseline. Patients were stratified according
to their use of beta-blockers as part of their background
therapy for chronic HF.
Follow-up. Patients returned for follow-up at two, four,
and six months and every three months thereafter. Physical
examination, review of symptoms, and adverse events were
assessed at each visit; quality-of-life assessment was per-
formed at one, four, and six months and every three months
thereafter; hematology, blood chemistry, and urinalysis were
performed at 4 and 6 months and every 6 months thereafter;
echocardiograms were obtained at 4 and 12 months and
every 6 months until the end of the study. Blood samples for
brain natriuretic peptide (BNP) and norepinephrine assays
were collected at 4, 12, and 24 months and at study end.
Outcome measures. The study was designed with two
primary end points: time to death and time to composite
end point of first mortality or morbidity, defined as death,
sudden death with resuscitation, hospital admission for HF,
or administration of intravenous inotropic or vasodilator
drugs for 4 h without hospital admission. The events
considered in the two primary end points were centrally
validated by the independent End Points Committee.
Secondary end points included changes in the following
from baseline to end point (last available observation after
randomization): ejection fraction, left ventricular end-
diastolic volume adjusted for BSA, quality-of-life scores,
and neurohormonal profile.
Quality of life was assessed with the Minnesota Living
with Heart Failure Questionnaire (MLHFQ) in centers in
the U.S., U.K., Australia, and Italy, where the questionnaire
has been validated.
A Val-HeFT substudy evaluated exercise capacity by the
6-min walk test after four months of double-blinded treat-
ment. Of the 633 patients included in the substudy, 35 were
not receiving ACE inhibitors as background therapy.
Statistical analysis. Inter-treatment comparisons of the
primary end points for patients not treated with an ACE
inhibitor were made using the log-rank test, and relative
risks with 95% confidence intervals were obtained for these
comparisons using a Cox regression model with prespecified
baseline co-variates, including NYHA class, ejection frac-
tion (above or below the median value), cause of HF
(ischemic or nonischemic), age (65 or65 years old), and
beta-blocker use or nonuse. Inter-treatment comparisons
for the first occurrence of the secondary mortality/morbidity
end points were also made using the log-rank test, and
relative risks for these variables were obtained from the Cox
regression model described earlier.
Inter-treatment comparisons for BNP, norepinephrine,
LVEF, LVIDD, and MLHFQ, as well as for the substudy
analysis of 6-min walk test, were made for patients not
treated with an ACE inhibitor, by using analysis of co-
variance (ANCOVA) adjusted for geographic region (U.S.
or non-U.S.), baseline values, beta-blocker usage (yes or
no), and treatment–baseline interaction. Changes over time
from baseline at each analyzed time point were expressed as
the least squares mean (LSM) value, based on the corre-
sponding ANCOVA.
Inter-treatment comparisons of sudden deaths and rea-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
BNP  brain natriuretic peptide
BSA  body surface area
HF  heart failure
LSM  least squares mean
LVEF  left ventricular ejection fraction
LVIDD  left ventricular internal diastolic diameter
MLHFQ  Minnesota Living with Heart Failure
Questionnaire
Val-HeFT  Valsartan Heart Failure Trial
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sons for permanent treatment discontinuation in patients
not treated with an ACE inhibitor were made using the
chi-square test. Inter-treatment comparisons for patients
not treated with an ACE inhibitor were based on the
Cochran-Mantel-Haenszel test for the number of hospital
admissions, stratified for beta-blocker usage and NYHA
class (I/II vs. III/IV), using modified ridit scores. Baseline
comparisons of ACE inhibitor versus non–ACE inhibitor
treatment and valsartan versus placebo within the non–
ACE inhibitor group were made using the chi-square and F
tests. A two-sided significance level of 0.05 was used for all
non–ACE inhibitor subgroup tests.
RESULTS
Of the 5,010 patients randomized in the Val-HeFT trial,
366 (7.3%) were not receiving an ACE inhibitor at ran-
domization.
Table 1 shows the baseline characteristics of patients
receiving and not receiving ACE inhibitors. Patients not
prescribed an ACE inhibitor were older and more fre-
quently female and had more severe HF (NYHA class
III/IV), a higher rate of ischemic etiology, and higher
LVEF and systolic blood pressure at baseline. However,
heart rate, S3 gallop, and LVIDD/BSA were similar in
patients receiving and not receiving ACE inhibitors. Pa-
tients not receiving an ACE inhibitor had higher levels of
circulating aldosterone and lower levels of plasma renin
activity than did patients receiving ACE inhibitors, al-
though circulating levels of norepinephrine and BNP were
similar.
There were few distinguishable differences in the baseline
summary characteristics of patients not treated with an
ACE inhibitor who were randomized to valsartan or pla-
cebo, except that more patients in the placebo group were in
NYHA class III/IV (p  0.022) and had more frequent S3
gallop (p  0.010), lower baseline diastolic blood pressure
(p  0.024), and higher baseline aldosterone levels (p 
0.006). The overall mean duration of observation for pa-
tients not treated with an ACE inhibitor was 22.68 months
(range 0.03 to 36.73).
Table 1. Baseline Characteristics of Patient Receiving or Not Receiving Angiotensin-Converting
Enzyme Inhibitors
ACE Inhibitor
Group (n  4,644)
Non–ACE Inhibitor Group
Total
(n  366)
Valsartan
(n  185)
Placebo
(n  181)
Age (yrs) 62.3  11.0* 67.2  10.4 66.6  10.3 67.7  10.4
Age 65 yrs (%) 45.6* 63.4 60.0 66.9
Females (%) 19.3* 28.7 24.3 33.1
Whites (%) 90.0* 95.1 95.1 95.0
NYHA class III–IV (%) 37.4* 47.0 41.1 53.0†
Ischemic etiology (%) 56.4* 67.5 69.2 65.7
Duration HF (months)
Median 36.0 36.0 36.0 36.0
Mean  SD 50.8  50.6* 56.3  58.0 57.8  61.9 54.8  53.9
Beta-blockers (%) 34.7 38.3 39.5 37.0
SBP (mm Hg) 124  19* 126  18 128  19 125  18
DBP (mm Hg) 76  11 76  10 77  9 75  11†
HR (beats/min) 73  13 73  12 73  12 73  13
S3 (%) 25.7 27.6 21.6 33.7†
LVEF (%) 26.6  7.2* 28.2  6.7 27.6  6.7 28.7  6.6
LVIDD/BSA (cm/m2) 3.7  0.5 3.6  0.5 3.6  0.5 3.7  0.6
MLHFQ score 32.2  22.9 35.2  23.8 35.0  21.9 35.3  25.8
(n  2,881) (n  220) (n  115) (n  105)
Serum creatinine (mol/l) 113.43  27.17 115.51  30.35 113.20  28.24 117.86  32.28
(n  4,637) (n  366) (n  185) (n  181)
Norepinephrine (pg/ml) 462  325 491  295 480  296 502  293
(n  3,989) (n  312) (n  159) (n  153)
BNP (pg/ml) 179  231 199  219 205  206 192  232
(n  3,993) (n  312) (n  159) (n  153)
Aldosterone (pg/ml) 132  120* 190  197 163  173 218  216†
(n  3,929) (n  311) (n  159) (n  152)
Plasma renin activity
(ng/ml per h)
15.1  24.3* 4.2  7.3 4.0  6.9 4.3  7.7
(n  3,978) (n  313) (n  159) (n  154)
*Statistically significant at p  0.05 when comparing ACE inhibitor group versus non–ACE inhibitor group. †Statistically
significant at p  0.05 when comparing valsartan versus placebo in non–ACE inhibitor group. Data are presented as the mean
value  SD or percentage of patients.
ACE  angiotensin-converting enzyme; BNP  brain natriuretic peptide; DBP  sitting diastolic blood pressure; HF 
heart failure; HR  heart rate; LVEF  left ventricular ejection fraction; LVIDD/BSA  left ventricular internal diastolic
diameter/body surface area; MLHFQ  Minnesota Living with Heart Failure Questionnaire; NYHA  New York Heart
Association; SBP  sitting systolic blood pressure; S3  third heart sound.
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Effects of valsartan on mortality, morbidity, and hospital
admission. Both all-cause mortality and the composite end
point of mortality and morbidity for patients not treated
with an ACE inhibitor were significantly reduced in the
valsartan treatment group as compared with the placebo
group (Fig. 1, Table 2A). All-cause mortality was 17.3% in
the valsartan group and 27.1% in the placebo group (reduc-
ing the relative risk by 33%, p 0.017), and the rates of first
hospital admission for HF were 13.0% and 26.5% in the
valsartan and placebo groups, respectively (reducing the
relative risk by 53%, p  0.0006). Sudden death was the
most frequent type of death in both the valsartan and
placebo groups: 16 of 32 deaths and 19 of 49 deaths,
respectively. There were very few sudden deaths with
resuscitation and use of intravenous inotropic therapy. The
favorable effect of valsartan on mortality and the composite
end point of morbidity and mortality was observed both in
the 140 patients receiving beta-blockers (relative risk reduc-
tions of 19% [p  NS] and 42%, respectively) and in the
226 patients not receiving beta-blockers (relative risk reduc-
tions of 42% and 44%, respectively).
Valsartan significantly reduced the total number of hos-
pital admissions for HF, both those adjudicated as primary
events and those classified by investigators, but had no effect
on total hospital admissions for reasons other than HF
(Table 2B).
Effects of valsartan on secondary variables and other
clinical events. The LVEF increased over time in both
treatment groups, but the increase was significantly greater
in patients randomized to valsartan than in those random-
ized to placebo (Fig. 2A). Valsartan also decreased the
Figure 1. (A) Kaplan-Meier curves for mortality in the valsartan (dotted
line) and placebo (solid line) groups (n  185 and 181, respectively)
without angiotensin-converting enzyme (ACE) inhibitor background ther-
apy (p  0.017 by log-rank test). (B) Kaplan-Meier curves for the
combined end point of mortality and morbidity in the valsartan (dotted
line) and placebo (solid line) groups without ACE inhibitor background
therapy (p  0.001 by the log-rank test). Risk ratio (RR) and 95%
confidence interval (CI) obtained using Cox regression.
Table 2. Clinical Events in Patients Not Treated With Angiotensin-Converting Enzyme
Inhibitors: A) Mortality and Morbidity End Points and B) Total Investigator-Assessed Hospital
Admissions
A
Valsartan
Group
(n  185)
Placebo
Group
(n  181) RR* 95% CI* p Value†
Primary end points
All-cause mortality 32 (17.3%) 49 (27.1%) 0.67 0.42–1.06 0.017‡
Mortality/morbidity 46 (24.9%) 77 (42.5%) 0.56 0.39–0.81  0.001‡
Secondary mortality/morbidity end
points (first occurrence)
Cardiovascular deaths 29 (15.7%) 40 (22.1%) 0.76 0.46–1.24 0.074
Nonfatal morbid event 24 (13.0%) 49 (27.1%) 0.46 0.28–0.76  0.001‡
Sudden death with resuscitation 1 (0.5%) 2 (1.1%) 0.46 0.04–5.25 0.529
Therapy for HF 0 1 (0.6%) — — —
Hospital admission for HF 24 (13.0%) 48 (26.5%) 0.47 0.29–0.78  0.001‡
B Valsartan Placebo Diff.§ % Diff. p Value¶
Hospitalization cause
All-cause 199 262 63 24.0 0.260
HF 51 117 66 56.4 0.010‡
Non–HF 148 145 3 2.1 0.567
*Risk ratio (RR) and 95% confidence interval (CI) obtained using Cox regression, adjusting for New York Heart Association
(NYHA) class, left ventricular ejection fraction baseline beta-blocker usage, etiology, and age group. †Based on log-rank tests.
‡Statistically significant at p  0.05. §Difference (valsartan  placebo); % Diff  100  Diff/placebo. ¶Based on the
Cochran-Mantel-Haenzel test for the number of hospital admissions stratified by beta-blocker usage and NYHA class, using
modified ridit scores.
HF  heart failure.
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LVIDD/BSA over time (Fig. 2B). At the last available
observation, patients randomized to valsartan had a signif-
icantly smaller mean LVIDD/BSA than did patients ran-
domized to placebo.
A favorable effect of valsartan was also observed on
plasma BNP and norepinephrine levels (Figs. 3A and 3B).
Valsartan tended to attenuate the increase in norepineph-
rine levels over time and significantly reduced the levels of
BNP over time, as compared with the placebo group. The
MLHFQ was administered to 57% of patients not pre-
scribed an ACE inhibitor (n  209). Valsartan improved
the MLHFQ score for these patients throughout the course
of the trial, although the difference was statistically signifi-
cant only at one year (Table 3).
The favorable effects of valsartan on clinical and physio-
logic end points were accompanied by a significant reduc-
tion in sitting systolic blood pressure, as compared with
placebo (Table 3). This blood pressure-lowering effect was
not associated with any reflex increase in heart rate.
With respect to the 35 patients included in the substudy
on exercise capacity, there was a statistically significant
increase in the walk distance in valsartan-treated patients as
compared with those who received placebo (50.3-m increase
with valsartan vs. 34.2-m decrease with placebo; LSM
treatment difference of 84.4 m; p  0.022)
Safety profile. Table 4 shows the rate of permanent dis-
continuation of study treatments. Overall, 82.7% and 75.1%
of patients not treated with an ACE inhibitor randomized
to valsartan or placebo, respectively, remained on study
treatment until the end of the follow-up period. Permanent
study treatment discontinuation due to adverse events were
comparable between the two groups. The rates of treatment
discontinuation due to symptomatic hypotension and renal
dysfunction were not different between the two treatment
groups, and none of the patients experienced angioedema or
cough.
The most common adverse events, regardless of study
Figure 2. Echocardiographic changes over time. (A) Least squares mean
(LSM) change (SEM) from baseline in left ventricular ejection fraction
(%). (B) LSM change from baseline in left ventricular internal diastolic
diameter/body surface area (cm/m2). The p values refer to the LSM
comparison between the valsartan (solid bars) and placebo (open bars)
groups by analysis of co-variance. n  total number of patients in the
valsartan and placebo treatment groups.
Figure 3. Neurohormonal changes over time: least squares mean (LSM)
changes from baseline in the plasma concentrations of norepinephrine (A)
and BNP (B). The p values refer to the LSM comparison between the
valsartan (solid bars) and placebo (open bars) groups by analysis of
co-variance. n  total number of patients in the valsartan and placebo
treatment groups.
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drug relationship, were dizziness (excluding vertigo) (44
[23.9%] for valsartan vs. 34 [18.9%] for placebo) and
hypotension (27 [14.7%] for valsartan vs. 10 [5.6%] for
placebo).
With respect to renal function, serum creatinine levels
increased from baseline to the last available evaluation in
both the valsartan and placebo groups. The mean increase
was slightly but significantly higher in the valsartan group
than in the placebo group (0.18  0.02 vs. 0.10  0.02
mg/dl, p  0.009).
DISCUSSION
The present analysis of Val-HeFT suggests that valsartan is
effective in reducing all-cause mortality and hospital admis-
sions for HF in patients not prescribed ACE inhibitors as
part of their background therapy. This was accompanied by
a significant increase in LVEF, a decrease in LVIDD/BSA
and BNP levels, and an attenuation of the increase in the
plasma norepinephrine concentration over time in the
valsartan group as compared with the placebo group. Sitting
systolic blood pressure was significantly lower in the valsar-
tan group at one and two years and at study end. The overall
incidence of adverse events was not significantly different
between the valsartan and placebo groups. Quality of life
was significantly improved in the valsartan group at one
year, with a trend toward sustained improvement at two
years and study conclusion. In patients receiving ACE
inhibitors, there was a trend toward a reduction in the
composite mortality/morbidity end point (relative risk
0.901, p 0.096), although the effect on all-cause mortality
was neutral (data on file at Novartis Pharma AG, Basel,
Switzerland).
Previous studies have suggested that significant numbers
of patients with HF are not being treated with ACE
inhibitors, despite clear evidence of a benefit from their
utilization (4,10–14). In the Study of Patients Intolerant of
Converting Enzyme inhibitors (SPICE) registry (4) and
other data bases, nearly 20% of patients with depressed left
ventricular function, as monitored by cardiologists, were not
prescribed ACE inhibitors because of a perceived drug
intolerance (2,14). In Val-HeFT, the proportion of the
population receiving an ACE inhibitor was high (93%).
This was probably because patients who had been prescribed
an ARB (increasingly used in ACE inhibitor–intolerant
patients) were excluded.
Patients who were enrolled in Val-HeFT and not pre-
scribed ACE inhibitors, most likely due to contraindications
or drug intolerance, have a baseline risk profile that is worse
than that of patients treated with ACE inhibitors. This
observation is consistent with that seen in the SPICE
registry, in which 9,580 patients at 105 centers in eight
countries were included. In that study, patients not pre-
scribed ACE inhibitors were older and had indicators of
more severe HF, as well (4).
The small pilot trial that followed the SPICE registry
showed that short-term treatment (12 weeks) with cande-
Table 3. Changes in Quality of Life (Assessed by the MLHFQ), Sitting SBP, and HR in
Patients Not Treated With Angiotensin-Converting Enzyme Inhibitors
Valsartan Placebo p Value
Change in MLHFQ score (LSM  SEM)
One year 4.15  1.78 (n  86) 1.01  2.11 (n  73) 0.047*
Two years 1.07  2.30 (n  48) 5.62  3.18 (n  27) 0.078
Last observation 0.98  1.71 (n  112) 3.17  1.98 (n  97) 0.095
SBP (mm Hg) (LSM  SEM)
One year 7.5  1.1 (n  150) 0.5  1.2 (n  133)  0.001*
Two years 8.4  1.8 (n  97) 0.6  2.0 (n  76) 0.001*
Last observation 8.1  1.2 (n  184) 3.2  1.2 (n  180) 0.004*
HR (beats/min) (LSM  SEM)
One year 2.4  0.8 (n  150) 0.3  0.8 (n  133) 0.065
Two years 2.4  1.0 (n  97) 3.6  1.2 (n  76) 0.430
Last observation 0.6  0.8 (n  184) 0.6  0.8 (n  180) 0.974
*Statistically significant at p  0.05. Data are presented as the least squares mean (LSM) change  SEM by analysis of
co-variance.
HR  heart rate; LSM  least squares mean; MLHFQ  Minnesota Living With Heart Failure Questionnaire; SBP 
sitting systolic blood pressure.
Table 4. Permanent Study Treatment Discontinuations
Valsartan
(n  185)
Placebo
(n  181)
Total
(n  366) p Value*
Adverse events 18 (9.7%) 23 (12.7%) 41 (11.2%) 0.367
Life-threatening laboratory abnormalities 1 (0.5%) 1 (0.6%) 2 (0.5%) 0.988
Hypotension† 1 (0.5%) 1 (0.6%) 2 (0.5%) 0.988
Other 12 (6.5%) 20 (11.1%) 32 (8.7%) 0.122
Total 32 (17.3%) 45 (24.9%) 77 (21.0%) 0.076
*By chi-square test. †Persistent standing systolic blood pressure 80 mm Hg or symptoms of hypotension.
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sartan was tolerated as well as placebo in patients with a
documented intolerance to ACE inhibitors (7). However,
until now, evidence from randomized trials of the efficacy of
ARBs on morbidity and mortality in this high-risk chronic
HF population has been lacking.
Val-HeFT tested the effects of valsartan versus placebo
on top of the prescribed therapy for patients with chronic
symptomatic HF, depressed left ventricular function, and
left ventricular dilation (8). In the patients not treated with
an ACE inhibitor included in the present analysis, 80%
were receiving diuretics, 38% beta-blockers, 59% digoxin,
and 7% spironolactone. Analysis of this subgroup allowed a
randomized comparison of the effect of valsartan on mor-
bidity, mortality, and physiologic measures, such as the
neurohormonal profile, left ventricular function, and quality
of life.
Despite the relatively low number of patients included in
this analysis, the significant reduction in morbidity and
mortality with the use of valsartan in patients not prescribed
ACE inhibitors confirms the pathogenetic role of the
renin-angiotensin-aldosterone system in the progression of
HF and its influence on the outcome of patients with HF.
Patients randomized to valsartan showed improvements
in terms of physiologic end points, consistent with the
beneficial effects on clinical events. These observations
further strengthen the reliability of the results and provide
information on the possible mechanisms that underlie the
benefits of valsartan. The improved neurohormonal profile
and the significant reduction in blood pressure confirm the
importance of the modulation of the renin-angiotensin-
aldosterone system and suggest that both hemodynamic and
neurohormonal effects played a role in determining the
beneficial effects of ARBs in these patients. These pharma-
cologic actions are also likely to be determinants of the
improvement in left ventricular function, as documented by
the significant increase in LVEF. Together, these positive
effects were associated with a better quality of life and
increased survival.
In this population of patients at high risk of clinical
events, the favorable effect of valsartan appears to be similar
to that obtained with ACE inhibitors, when these drugs
were compared with placebo (15,16). In the present study,
the patients not treated with an ACE inhibitor who were
randomized to valsartan showed a reduction in the relative
risk of all-cause mortality of 33%, a figure very similar to
that observed (27%) for patients receiving enalapril in the
COoperative North Scandinavian ENalapril SUrvival Study
(CONSENSUS) (15). It is also interesting that the reduc-
tion in sitting systolic blood pressure was similar for the
patients treated with valsartan (but not ACE inhibitors) in
Val-HeFT and those treated with enalapril in the Studies
Of Left Ventricular Dysfunction (SOLVD), thus confirm-
ing the importance of angiotensin in supporting blood
pressure in HF.
An important feature of ARBs is their low adverse-effect
profile. The favorable effects of valsartan were obtained
without the occurrence of relevant adverse reactions. Nearly
83% of patients not treated with an ACE inhibitor who
were randomized to valsartan completed the trial without
permanently discontinuing treatment, and 77% were ti-
trated to the target dose of 320 mg/day. Unexpectedly, the
number of patients not treated with an ACE inhibitor who
discontinued valsartan was lower than the number of pa-
tients randomized to placebo. A similar tolerability profile
was observed in the SPICE trial, where 270 patients with
HF intolerant to ACE inhibitors were treated with cande-
sartan, but only for a short period (12 weeks) (7).
There are some limitations to be noted in the present
analysis of patients not treated with an ACE inhibitor in the
Val-HeFT data base. Although the size of the non–ACE
inhibitor group was small, the consistent direction and
magnitude of the effects favoring valsartan, in terms of
clinical and physiologic end points, together with the
pharmacologic and pathophysiologic rationale on its use in
these patients, tend to make these observations interesting
and potentially acceptable for recommendations in clinical
practice. In any case, as suggested by previous contradictory
conclusions derived from underpowered studies (17,18),
these results should be interpreted with caution and need to
be confirmed in larger randomized trials, and in this respect,
the final results of the Candesartan in Heart failure—
Assessment of Reduction in Mortality and morbidity
(CHARM) trial are awaited with great interest (19).
Clinical implications and conclusions. The findings of
this analysis of the Val-HeFT data base suggest that
valsartan can improve morbidity and mortality in patients
not treated with ACE inhibitors, but with other background
therapy, including beta-blockers. Valsartan not only inhibits
this system effectively, but also has an excellent safety profile
in this group of high-risk patients. Although this subgroup
of patients from Val-HeFT is small, the preliminary find-
ings suggest that valsartan can serve as a safe, effective
substitute for ACE inhibitors in the management of HF.
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